Julia Jackman has followed Bonus Track with this queer fantasy-fable that has a streak of earnestness to go with the romantasy energy and gorgeous costumes from designer Susie Coulthard. It’s adapted by Jackman from Isabel Greenberg’s 2016…
Making an All-NBA First Team is an incredible individual accomplishment, especially when considering that only five players are awarded with that honor each year. This article spotlights the five New York Knicks who have earned this accolade…
Behringer has shrunk its UB-Xa synth once again, with the launch of the UB-Xa Mini. According to the brand, it delivers “big sound in a small package”.
Behringer released its original UB-Xa in 2023, and it later went on to become the
During the study period, there were 554 episodes of Citrobacter spp. BSI in 525 patients. In total, eighteen patients each experienced two episodes of CBSI, four patients had three episodes of CBSI and one patient had four episodes of CBSI. The most common species was Citrobacter freundii complex (47%, n = 261), followed by Citrobacter koseri (42%, n = 233) and Citrobacter non-freundi complex, non-koseri (11%, n = 60). The median age of the included patients was 77 years (range 0-100), and 70% of the patients were men (n = 374). The median CCI was 6 (range 0–15) and 28% (n = 146) of patients were considered immunocompromised (Table 1). Out of all 534 episodes of CBSI, complete medical records were available for 537 episodes (97%).
Table 1 Baseline characteristics and clinical determinants of included patients. All percentages calculated on available data
The incidence of Citrobacter koseri increased during the study period
The age and sex-standardized incidence rate of Citrobacter spp. BSI increased from 3.4 episodes per 100 000 person-years in 2013 to 4.9 episodes per 100 000 person-years in 2023 (Fig. 1).
Fig. 1
Incidence of Citrobacter spp. during the study period. EASR = estimated age- and sex standardized rate. CI L = Confidence Interval Low. CI H = Confidence Interval High
The increase was not statistically different from zero, with an APC of 3.2 (95% CI: -0.2% to 6.6%) for the entire study period. Separated into species, the crude rate of Citrobacter koseri and Citrobacter freundi complex increased from 0.9 to 1.9 in 2013, to 2.1 and 2.1 in 2023, respectively (Table A1). While the increase in crude incidence of Citrobacter freundi complex BSI was not statistically different from zero (APC of 2.74 95%CI: -2.3% to 8.1%), the crude incidence of increase of Citrobacter koseri during the study period was statistically significant (APC of 7.56 95%CI: 4.6% to 10.6%). Most BSI occurred in ages 75–84 years (Figure A1).
Microbiological findings and antimicrobial resistance
Resistance rates were statistically significantly higher for Citrobacter freundii compared to Citrobacter koseri for all antimicrobials compared, apart from gentamicin (Table A2). For Citrobacter freundii, resistance rates were 15% (n = 40) for ceftazidime, 7% (n = 18) for ciprofloxacin, 11% (n = 28) for piperacillin-tazobactam, 8% (n = 20) for trimethoprim/sulfamethoxazole and 1% (n = 6) and 2% (n = 9) were resistant against gentamicin and tobramycin, respectively. For Citrobacter koseri, 0.4% (n = 1) strains were resistant towards ciprofloxacin, 2% (n = 4) towards piperacillin-tazobactam and 1% (n = 2) towards trimethoprim/sulfamethoxazole. No strains were resistant towards ceftazidime, gentamicin or tobramycin. No carbapenem-resistant strains were found in the study.
In total, 38% (n = 208) of the BSI episodes were polymicrobial, with 306 pathogens other than Citrobacter detected. The most common microbiological findings in polymicrobial blood cultures other than Citrobacter spp. were Enterococcus spp. (32%, n = 66), Klebsiella spp. (25%, n = 51) and Escherichia coli (24%, n = 49) (Table 2).
Table 2 Microbiological findings in polymicrobial BSI other than Citrobacter species
Citrobacter bloodstream infection is most often associated with urinary tract infection
According to the medical records, the most common etiology of Citrobacter BSI was urinary tract infection 48% (n = 245). Urine cultures were obtained in 404 (73%) of BSI episodes, of which 373 (92%) were acquired prior to antimicrobials had been initiated. Out of all 404 urine cultures, 187 (46%) were positive for Citrobacter spp. Primary BSI constituted 24% (n = 134) of all Citrobacter BSI, after which intraabdominal source of infection was common 19% (n = 95) (Fig. 2).
Fig. 2
Infection sources for Citrobacter BSI. UTI = urinary tract infection. PBSI = primary bloodstream infection. IRFM = infection related to a foreign material (portacath, central venous catheter or orthopaedic prosthesis). EGEI = endocarditis/graft/endograft infection
Citrobacter bloodstream infection is associated with healthcare
In total, fever at blood culturing or within 48 h was present for 387 (70%) episodes and patients reported shivers in 252 (46%) episodes. The median NEWS score when blood cultures were obtained was 4 (range 0–18), the median CRP value was 108 mg/L (range < 4-563) and the median leukocyte count in blood was 12.9 109/L (0.1–92) (Table 1). In nine episodes (2%) of Citrobacter BSI, patients were managed as outpatients, whereas hospitalization was required for all other BSI episodes. In total, 197 (36%) Citrobacter BSI were community acquired, 81 (15%) episodes were nosocomial and 255 (46%) were health care associated (Fig. 3). The median length of stay at hospital was 8 days (range 0-680).
Fig. 3
Mode of acquisition of Citrobacter BSI
Outcome
Out of all 554 Citrobacter BSI episodes, septic shock was seen in 25 (4%) episodes and in 38 (7%) episodes patients required intensive care. The 30-, 90-, 180- and 365-days mortality rates were 12%, 18%, 23% and 25%, respectively (Table 3). Although the 90-, 180- and 365-day mortality rates were significantly higher for C. freundii-complex BSI compared to C. koseri BSI, there was no statistically significant difference in mortality rates between C. freundii complex BSI compared to C. koseri BSI in the Kaplan-Meier estimator (Fig. 4). There was no statistical difference in all-cause mortality within 90 days between patients with one episode of Citrobacter spp. BSI (19%) and patients with two or more episodes (22%, p = 0.74).
Table 3 Outcome of Citrobacter spp. BSI. ICU = intensive care unit
Fig. 4
Kaplan-Maier estimates of mortality in C. freundii complex and C. koseri BSI. p = 0.09
Differences in patient characteristics between BSI due to C. freundii complex and C. koseri
There were no differences in age, CCI-score, rate of immunosuppression or substance abuse between patients with BSI caused by C. freundii complex and C. koseri. However, a greater proportion of men suffered from C. koseri BSI compared to C. freundii-complex BSI (p = 0.01). The rate of polymicrobial BSI (p = 0.0001) as well as BSIs with abdominal source of infection (p = 0.03) were greater for C. freundii complex compared to BSIs due to C. koseri. Patients with C. koseri BSI had to a greater extent UTI symptoms (p = 0.005), positive nitrite dipsticks (p = 0.006), and analogous Citrobacter species cultured in the urine (p = < 0.0001) compared to patients with BSI due to C. freundii complex (Table 4).
Table 4 Differences in clinical characteristics between patients with C. freundii complex and C. koseri
Univariate and multivariate analysis of variables associated with mortality within 90 days
In the univariate model, female sex, higher CCI score, immunosuppression and longer duration of hospitalisation was associated with death within 90 days of Citrobacter BSI, as was lack of UTI symptoms and non-community acquired infection (Table 5).Similarly, primary BSI and abdominal focus was significantly more common in patients that died within 90 days. In the multivariate model, higher Charlson comorbidity index, immunosuppression, higher CRP, and a urinary tract focus, were independently associated with 90 days mortality, while age, sex, septic shock, polymicrobial culture and fever were not (Table 6).
Table 5 Univariate logistic regression model
Table 6 Multivariate analysis of variables associated with mortality within 90 days
The parent company behind Secret Cinema, the London-based immersive film and TV business, has been bought by the Hollywood power broker Ari Emanuel.
TodayTix, which is changing hands for an undisclosed sum, marks the latest acquisition by Emanuel’s new global events company, Mari, which bought the Frieze global art fair and publishing group in May for $200m (£148m).
Mari is backed by Apollo Global Management and RedBird Capital Partners, which has invested in the football clubs Liverpool FC and AC Milan and is trying to push through a deal to buy the Telegraph newspaper group.
Emanuel already runs the company behind World Wrestling Entertainment and the Ultimate Fighting Championship.
TodayTix will now join the fold, after being bought from Great Hill Partners, a private equity company which took a controlling stake in the business in 2019.
TodayTix had its start selling theatre tickets for Broadway and West End shows. It later branched out to New York-based events including a supper club in Times Square and concerts in Brooklyn, before buying Secret Cinema in a $100m (£88m) deal in 2022.
Secret Cinema is best known for its mystery screenings at undisclosed venues, involving sets and interactive performances. It also has deals with Disney and Netflix to create immersive experiences for shows including Guardians of the Galaxy and Stranger Things.
Brian Fenty, who founded TodayTix with fellow Broadway producer Merritt Baer in 2013, told the Guardian the takeover followed an “incredibly competitive” bidding process and said Mari’s ownership would create opportunities for the Secret Cinema producer and Emanuel’s other ventures.
Mari will benefit from access to 20 million TodayTix members and Fenty said his company could expand ticketing options to sports and art venues.
He said: “As a single venue, for example, you only market to people who have bought from you before, whether or not they want to see that type of programming again. And in our case … we’re able to look at how people are behaving across a wide array of events and types of shows.”
skip past newsletter promotion
after newsletter promotion
Emanuel has acquired tennis assets including the Miami Open and Madrid Open tournaments from Endeavor this year. He stepped down from Endeavor after it was bought by the private equity company Silver Lake earlier this year but remains executive chair of its Hollywood talent agency.
Fenty will remain chief executive of TodayTix and will join Mari’s executive team.
TodayTix employs about 200 staff, with half based in London. “We are big believers that the UK and London can be sort of the pole market from which to build many of these brands and events,” said Fenty, who moved his family from New York to London during the pandemic.
When asked whether he had any concerns about tax changes in the budget next month that could hit consumer spending on live events, Fenty replied: “I’m an entrepreneur. So I hope that the UK continues to create a great home for entrepreneurs and the arts, and I hope that the budget does nothing to take away from that.”
New embedded payment service will deliver seamless merchant experience, advanced BNPL options, and a unified balance dashboard, launching for US merchants in 2026.
AUSTIN, Texas — October 20, 2025 — Commerce, (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of BigCommerce, today announced a new embedded payment processing solution available exclusively to BigCommerce merchants. Powered by PayPal (Nasdaq: PYPL), BigCommerce Payments is slated for a U.S. launch in 2026, with international expansion planned in subsequent phases.
This strategic expansion builds on more than a decade of close partnership between Commerce and PayPal, marking a new chapter in their collaboration. Through this optional co-branded integration, merchants will gain access to advanced payment capabilities, simplified account management, and buy now, pay later (BNPL) via PayPal’s Pay Later offering, all seamlessly managed within the BigCommerce Control Panel.
“Commerce is thrilled to extend our longstanding partnership with PayPal and work together on this new payments solution,” said Travis Hess, CEO at Commerce. “BigCommerce Payments represents a major step forward in creating a seamless and simplified intelligent commerce experience for Commerce merchants. By embedding PayPal’s trusted payment solutions directly into our platform, we will give merchants more control, visibility and flexibility to grow their businesses with confidence.”
“Together with Commerce, we’re not just addressing the needs of today’s merchants, we’re empowering them to seize the future with confidence and agility,” said Michelle Gill, Executive Vice President and General Manager, Small Business & Financial Services, PayPal. “By bringing together PayPal’s world-renowned reliability, security and global reach with Commerce’s merchant-focused platform, we’re helping merchants thrive in the next era of ecommerce.”
The BigCommerce Payments architecture is built to ensure transparency and merchant ownership. While BigCommerce Payments is co-branded and embedded into BigCommerce, the merchant’s payment relationship remains directly with PayPal. BigCommerce Payments will introduce a dedicated “Money” dashboard within the BigCommerce Control Panel, offering merchants direct access to manage and monitor their payments and balance activity. Features include:
Real-time balance insights
Top-ups and payouts
Bank and card connections
Currency management
This embedded experience will mirror key capabilities of the merchant’s PayPal dashboard, providing a streamlined experience where merchants can manage their payments along with the rest of their business through a single portal and reducing the need to toggle between multiple systems. For more advanced settings, the BigCommerce Payments settings page will provide direct access to the PayPal dashboard.
In coordination with PayPal, BigCommerce will enable the migration of existing merchants currently utilizing PayPal Complete Payments (PPCP). These merchants will receive personalized communications, offering them the option to seamlessly transition to BigCommerce Payments.
About Commerce
Commerce (Nasdaq: CMRC) empowers businesses to innovate, grow, and thrive by providing an open, AI-driven commerce ecosystem. As the parent company of BigCommerce, Feedonomics, and Makeswift, Commerce connects the tools and systems that power growth, enabling businesses to unlock the full potential of their data, deliver seamless and personalized experiences across every channel, and adapt swiftly to an ever-changing market. Trusted by leading businesses like Coldwater Creek, Cole Haan, Harvey Nichols, King Arthur Baking Co., Mizuno, Perry Ellis, Puma, SportsShoes, and Uplift Desk, Commerce delivers the storefront control, optimized data, and AI-ready tools businesses need to grow, serve diverse buyers, and operate with confidence in an increasingly intelligent, multi-surface world. For more information, visit commerce.com or follow us on X and LinkedIn.
About PayPal
PayPal has been revolutionizing commerce globally for more than 25 years. Creating innovative experiences that make moving money, selling, and shopping simple, personalized, and secure, PayPal empowers consumers and businesses in approximately 200 markets to join and thrive in the global economy. For more information, visit https://www.paypal.com, https://about.pypl.com/ and https://investor.pypl.com/.
BigCommerce®, the Commerce logo, and other brands are the trademarks or registered trademarks of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owner.
BBC
